1635-+

OCI 20 2000 AUTO

2000	Pate	Approved for earth and Trademark Office:	PTO/SB/21 (modified) use through xx/xx/xx, OMB 0651-0031 J.S. DEPARTMENT OF COMMERCE	
	ent of Commerce Frademark Office	Application Number	10/008,789	
		Filing Date	November 8, 2001	
TRANSMITTAL F	ORM	First Named Inventor	C. Frank Bennett et al.	
(to be used for all correspondence dur filed application)	ing pendency of	Group Art Unit Number	1635	
		Examiner Name	Terra C. Gibbs	
Total Number of Pages in This Submis	sion 5**	Attorney Docket Number	23546-07724 (RTS-0333)	
EI	NCLOSURES	(check all that appl	v)	
Fee Transmittal Form (in duplicate Check Enclosed Return Receipt Postcard Response to Notice to File Missing Assignment & Recordation Cover Declaration Power of Attorney Application Data Sheet Information Disclosure Statement Copies of IDS Cited Reference Request for Corrected Filing Receipt Request for Correction of Recorded Amendment/Response: [1] Page After Final Status Request Revocation and Substitute Power REMARKS: ** IDS references are not in	g Parts Sheet & PTO-1449 ferences eipt ed Assignment ge(s) of Attorney	Appeal Commur Interferences Appeal Commur (Appeal Notice, Certified Copy o After Allowance	raftsperson	
SIGNATURE OF ATTORNEY OR AGENT				
Signature: / / / / / / / / / / / / / / / / / / /				
Attorney/Reg. No.: Susan T. Hubl, Ph.D., Reg. No. 47,668 Dated: October 14, 2003				
CERTIFICATE OF MAILING I hereby certify that this correspondence, including the enclosures identified above, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Non Fee Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.				
Signature: Mum 1 Hwl				
Typed or Printed Name: Susan T. I	lubl, Ph.D., Pater	nt Agent	Dated: October 4 , 2003	

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. TE TEABER

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Submitted Sheet

Complete if Known			
Application No. 10/008,789			
Filing Date	November 8, 2001		
First Named Inventor	C. Frank Bennett et al.		
Art Unit	1635		
Examiner Name	Terra C. Gibbs		
Attorney Docket Number	23546-07724 (RTS-0333)		

U.S. PATENT DOCUMENTS				
***		Document No.		
Examiner Initials*	Cite No.1	Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	US-5,801,154	08/06/1997	Baracchini
	A2	US-		
<u> </u>	А3	US-		
	A4	US-		

FOREIGN PATENT DOCUMENTS					
		Foreign Patent Document			
Examiner Initials*	Cite No.1	Country Code ³ – Number ⁴ Kind Code ⁵ (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
	B1				
	B2				

		OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C1	Branch A. A Good Antisense Molecule is Hard to Find. TIBS, Vol. 23, pp 45-50, (Feb. 1998).	
	C2 _{,4}	Fritz et al. Cationic Polystyrene Nanoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides. Journal of Colloid and Interface Science, Vol. 195: 272-288 (1997).	
	C3 ,	Jen, et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells, Vol. 18 (2000).	
	C3 °	Schneider et al. Forschungszentrum Karlsruhe, FZKA 6587, pp 1-139 (2001), see abstract.	
	C4	Search Report from PCT/US02/35479	
	C5		

23546/07724/SF/5108075.1

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CANTS:

C. Frank Bennett et al.

APPLICATION NO.:

10/008,789

FILING DATE:

November 8, 2001

TITLE:

ANTISENSE MODULATION OF THYROID HORMONE RECEPTOR

INTERACTOR 6 EXPRESSION

EXAMINER:

1635

GROUP ART UNIT:

Terra C. Gibbs

ATTY. DKT. NO.:

23546-07724 (RTS-0333)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date shown below:

Dated: October

Musan T. Hubl, Ph.D., Reg. No. 47,668

MAIL STOP NON-FEE AMENDMENT COMMISSIONER FOR PATENTS P. O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner. Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

nental Informa	ation Disclosure Statement is being filed:
within three	months of the filing date of the application, or date of entry
into the natio	onal stage of an international application, or before the mailing
date of a first	t office action on the merits, whichever event last occurred;
before the ma	ailing of a first official action after the filing of a request for
continued ex	amination (RCE) under 37 CFR § 1.114;
after three m	onths of the filing date of this national application or the date
	e national stage in an international application, or after the
	of the first official action on the merits, whichever event last
occurred, but	before the mailing date of the first to occur of either: (1) a
	under 37 CFR §1.113; or (2) an action that otherwise closes
	n the application, and:
attac	hed hereto is the fee set forth under 37 CFR §1.17(p) for
subn	nission of this Information Disclosure Statement under 37
CFR	.§ 1.97(c); OR
⊠ App	licant certifies pursuant to 37 CFR § 1.97(e) that:
\boxtimes	each item of information contained in this Information
	Disclosure Statement was first cited in a communication
	from a foreign patent office in a counterpart foreign
	application not more than three months prior to the filing of
	this Statement; OR
	no item of information contained in this Information
	Disclosure Statement was cited in a communication from a
	foreign patent office in a counterpart foreign application
	and, to the knowledge of the person signing this
	certification after making reasonable inquiry, no item of
	information contained in this Statement was known to any
	individual designated under 37 CFR § 1.56(c) more than
	three months prior to the filing of this Statement;
before the pa	ayment of the issue fee but after the mailing date of the first to
occur of eith	er: (1) a final action under 37 CFR § 1.113; or (2) an action
that otherwis	se closes prosecution in the application, and:
☐ Appl	icant certifies pursuant to 37 CFR. § 1.97(e) that:
	each item of information contained in this Information
	Disclosure Statement was cited in a communication from a
	foreign patent office in a counterpart foreign application not
	more than three months prior to the filing of this Statement;
	or
	within three into the nation date of a first before the macontinued exafter three exafter three macontinued exafter three exafter th

	[a	Discloration foreign and, to certific inform individuals.	on of information contained in this Information obsure Statement was cited in a communication from a material patent office in a counterpart foreign application to the knowledge of the person signing this cation after making reasonable inquiry, no item of mation contained in this Statement was known to any dual designated under 37 CFR § 1.56(c) more than months prior to the filing of this Statement; AND to is the fee set forth under 37 CFR §1.17(p) for	
				f this Information Disclosure Statement under 37	
			CFR.§ 1.97(c); OR the issue fee. Applicant request that the information	
	(contained according	d in this Info	rmation Disclosure Statement be placed in the file § 1.97(i), although the information may not be	
	applicat referenc	This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. [APPLICATION NUMBER], filed on [FILING DATE], and the references cited therein are hereby referenced, but are not required to be provided in this application under 37 CFR § 1.98(d).			
	cited in and the § 1.56(c	a commicommun) more tl	unication fro	ntained in this Information Disclosure Statement was om a foreign patent office in a counterpart application, not received by any individual designated in 37 CFR ys prior to the filing of this Information Disclosure d).	
\boxtimes	Application Disclosu			e is required for the consideration of this Information	
Consi	deration o	f the list	ed reference	s and favorable action are solicited.	
				Respectfully submitted, C. FRANK BENNETT et al.	
Dated: Octob	per / C	}	, 2003	By:	